Core Viewpoint - Vivani Medical, Inc. is advancing its miniature, ultra long-acting drug implants aimed at improving patient adherence in chronic disease treatment, particularly in the GLP-1 drug class [1][4][5] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic implants using its proprietary NanoPortal™ technology [4] - The company’s lead programs include NPM-115 (exenatide implant) and NPM-139 (semaglutide implant), designed for chronic weight management with administration once or twice a year [4] - Vivani is also developing NPM-119, a six-month GLP-1 implant for type 2 diabetes treatment [4] Upcoming Events - CEO Adam Mendelsohn will present on "Addressing Patient Adherence: Advances in Drug Delivery" at the AAPS workshop on May 14, 2025 [2] - A panel discussion featuring Dr. Mendelsohn will address key hurdles and trends in GLP-1 drug development on the same day [3] Market Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [5] - The current GLP-1 landscape includes over 50 new molecular entities in clinical development, positioning Vivani's differentiated portfolio as a potential attractive option for patients and healthcare providers [5]